BioCentury | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

...ClinicalTrials.gov, HDAC6 inhibitor citarinostat from Celgene Corp. (NASDAQ:CELG) in combination with cancer vaccine PVX-410 from OncoPep Inc....
...Science and Celgene did not respond to requests for comment in time for publication, and OncoPep...
BioCentury | Dec 6, 2016
Clinical News

PVX-410: Ph Ib started

...PVX-410 every 2 weeks and durvalumab given with the fourth and sixth dose of PVX-410. OncoPep...
...It is in Phase III testing to treat bladder, head and neck and lung cancers. OncoPep Inc....
...Treat triple-negative breast cancer (TNBC) Endpoint: Safety; immune response Status: Phase Ib started Milestone: NA Alicia Parker PVX-410 OncoPep Inc. SLAM...
BioCentury | Dec 6, 2016
Clinical News

Durvalumab: Ph Ib started

...PVX-410 every 2 weeks and durvalumab given with the fourth and sixth dose of PVX-410. OncoPep...
BioCentury | Dec 1, 2016
Clinical News

PVX-410: Ph Ib started

...will receive PVX-410 and Revlimid every other week and durvalumab once monthly for 3 months. OncoPep...
...in Phase III trials to treat bladder cancer, head and neck cancer and lung cancer. OncoPep Inc....
...light chain and urinary free light chain Status: Phase Ib started Milestone: NA Alicia Parker PVX-410 Dana-Farber Cancer Institute OncoPep Inc. SLAM...
BioCentury | Dec 1, 2016
Clinical News

Durvalumab: Ph Ib started

...will receive PVX-410 and Revlimid every other week and durvalumab once monthly for 3 months. OncoPep...
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: X-box binding protein 1 (XBP1)

...steps include testing XBP1 inhibition in additional cancer models and in combination with cancer immunotherapies. OncoPep Inc....
BioCentury | Sep 1, 2014
Financial News

OncoPep completes venture financing

OncoPep Inc. , North Andover, Mass. Business: Cancer Date completed: 2014-08-28 Type: Venture financing Raised: $6.9 million Investors: Leukemia & Lymphoma Society ; angel investors; individual investors; existing investors WIR Staff...
BioCentury | Feb 4, 2013
Clinical News

PVX-410: Phase I/IIa started

...poly-ICLC ) adjuvant, a TLR3 agonist, in 13 patients. Last year, the institute granted OncoPep...
...to develop and commercialize multi-peptide cancer vaccine technology, including PVX-410 (see BioCentury, Feb. 20, 2012). OncoPep Inc....
BioCentury | Mar 5, 2012
Emerging Company Profile

OncoPep: Smoldering solution

...believes could become the treatment of choice based on its anticipated safety profile. In February, OncoPep...
...against MM cells ex vivo compared with CTLs produced by the individual peptides. Peterkin said OncoPep's...
...Boston, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. OncoPep Inc. , North Andover, Mass. Sidebars OncoPep Inc....
BioCentury | Feb 20, 2012
Company News

OncoPep, Dana-Farber Cancer Institute deal

...OncoPep exclusive, worldwide rights to develop and commercialize multi-peptide cancer vaccine technology, including PVX-410 . OncoPep...
...cell-surface glycoprotein CS1 and syndecan 1 ( SDC1 , CD138 ). Details were not disclosed. OncoPep Inc....
Items per page:
1 - 10 of 11
BioCentury | Sep 11, 2019
Translation in Brief

Cold Spring Harbor team finds off-target activity can drive antitumor effects

...ClinicalTrials.gov, HDAC6 inhibitor citarinostat from Celgene Corp. (NASDAQ:CELG) in combination with cancer vaccine PVX-410 from OncoPep Inc....
...Science and Celgene did not respond to requests for comment in time for publication, and OncoPep...
BioCentury | Dec 6, 2016
Clinical News

PVX-410: Ph Ib started

...PVX-410 every 2 weeks and durvalumab given with the fourth and sixth dose of PVX-410. OncoPep...
...It is in Phase III testing to treat bladder, head and neck and lung cancers. OncoPep Inc....
...Treat triple-negative breast cancer (TNBC) Endpoint: Safety; immune response Status: Phase Ib started Milestone: NA Alicia Parker PVX-410 OncoPep Inc. SLAM...
BioCentury | Dec 6, 2016
Clinical News

Durvalumab: Ph Ib started

...PVX-410 every 2 weeks and durvalumab given with the fourth and sixth dose of PVX-410. OncoPep...
BioCentury | Dec 1, 2016
Clinical News

PVX-410: Ph Ib started

...will receive PVX-410 and Revlimid every other week and durvalumab once monthly for 3 months. OncoPep...
...in Phase III trials to treat bladder cancer, head and neck cancer and lung cancer. OncoPep Inc....
...light chain and urinary free light chain Status: Phase Ib started Milestone: NA Alicia Parker PVX-410 Dana-Farber Cancer Institute OncoPep Inc. SLAM...
BioCentury | Dec 1, 2016
Clinical News

Durvalumab: Ph Ib started

...will receive PVX-410 and Revlimid every other week and durvalumab once monthly for 3 months. OncoPep...
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: X-box binding protein 1 (XBP1)

...steps include testing XBP1 inhibition in additional cancer models and in combination with cancer immunotherapies. OncoPep Inc....
BioCentury | Sep 1, 2014
Financial News

OncoPep completes venture financing

OncoPep Inc. , North Andover, Mass. Business: Cancer Date completed: 2014-08-28 Type: Venture financing Raised: $6.9 million Investors: Leukemia & Lymphoma Society ; angel investors; individual investors; existing investors WIR Staff...
BioCentury | Feb 4, 2013
Clinical News

PVX-410: Phase I/IIa started

...poly-ICLC ) adjuvant, a TLR3 agonist, in 13 patients. Last year, the institute granted OncoPep...
...to develop and commercialize multi-peptide cancer vaccine technology, including PVX-410 (see BioCentury, Feb. 20, 2012). OncoPep Inc....
BioCentury | Mar 5, 2012
Emerging Company Profile

OncoPep: Smoldering solution

...believes could become the treatment of choice based on its anticipated safety profile. In February, OncoPep...
...against MM cells ex vivo compared with CTLs produced by the individual peptides. Peterkin said OncoPep's...
...Boston, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. OncoPep Inc. , North Andover, Mass. Sidebars OncoPep Inc....
BioCentury | Feb 20, 2012
Company News

OncoPep, Dana-Farber Cancer Institute deal

...OncoPep exclusive, worldwide rights to develop and commercialize multi-peptide cancer vaccine technology, including PVX-410 . OncoPep...
...cell-surface glycoprotein CS1 and syndecan 1 ( SDC1 , CD138 ). Details were not disclosed. OncoPep Inc....
Items per page:
1 - 10 of 11